for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ABIOMED, Inc.

ABMD.OQ

Latest Trade

181.23USD

Change

-4.02(-2.17%)

Volume

46,551

Today's Range

178.74

 - 

185.58

52 Week Range

155.23

 - 

364.07

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Abiomed Announces Q2 FY 2020 Revenue Of $205 Million And 29.4% Operating Margin

Oct 31 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED ANNOUNCES Q2 FY 2020 REVENUE OF $205 MILLION AND 29.4% OPERATING MARGIN.SEES FY 2020 REVENUE $885 MILLION TO $925 MILLION.Q2 REVENUE $205 MILLION VERSUS REFINITIV IBES ESTIMATE OF $206.4 MILLION.Q2 GAAP EARNINGS PER SHARE $0.28.Q2 EARNINGS PER SHARE ESTIMATE $0.93 -- REFINITIV IBES DATA.MAINTAINING ITS FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 28% TO 30%.

FDA Post Approval Study Demonstrates Timely Identification Of Right Heart Failure And Early Use Of Impella Rp Leads To Higher Survival

Oct 25 (Reuters) - Abiomed Inc <ABMD.O>::FDA POST APPROVAL STUDY DEMONSTRATES TIMELY IDENTIFICATION OF RIGHT HEART FAILURE AND EARLY USE OF IMPELLA RP LEADS TO HIGHER SURVIVAL.

Abiomed Receives FDA PMA Approval For Impella 5.5 With SmartAssist

Sept 25 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED RECEIVES FDA PMA APPROVAL FOR IMPELLA 5.5 WITH SMARTASSIST, A MINIMALLY INVASIVE, FORWARD FLOW HEART PUMP.ABIOMED RECEIVES FDA PMA APPROVAL FOR IMPELLA 5.5 WITH SMARTASSIST, A MINIMALLY INVASIVE, FORWARD FLOW HEART PUMP.ABIOMED - IMPELLA 5.5 HAS RECEIVED U.S. FDA PRE-MARKET APPROVAL FOR SAFETY & EFFICACY IN THERAPY OF CARDIOGENIC SHOCK FOR UP TO 14 DAYS.

Abiomed Says Highest Court In Germany Affirms Strength Of Its Patents

Sept 23 (Reuters) - Abiomed Inc <ABMD.O>::HIGHEST COURT IN GERMANY AFFIRMS STRENGTH OF ABIOMED’S PATENTS.ABIOMED - FEDERAL COURT OF JUSTICE IN GERMANY RECENTLY RULED IN FAVOR OF CO IN A PATENT CHALLENGE FILED BY THORATEC IN 2015.ABIOMED INC - WILL PROCEED IN ADDITIONAL LITIGATION PROCEEDINGS FILED AGAINST THORATEC.

Abiomed Comments On Centers For Medicare & Medicaid Services Final Rule For Inpatient Prospective Payment System

Aug 5 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED INC - COMMENTS ON CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) FINAL RULE FOR INPATIENT PROSPECTIVE PAYMENT SYSTEM (IPPS).

Abiomed Q1 GAAP Earnings Per Share $1.93

Aug 1 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED ANNOUNCES Q1 FY 2020 REVENUE OF $208 MILLION AND 29.2% OPERATING MARGIN.Q1 GAAP EARNINGS PER SHARE $1.93.SEES FY 2020 REVENUE UP 15 TO 20 PERCENT.SEES FY 2020 REVENUE $885 MILLION TO $925 MILLION.Q1 REVENUE $208 MILLION VERSUS REFINITIV IBES ESTIMATE OF $210.7 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.97 -- REFINITIV IBES DATA.BOARD OF DIRECTORS HAS AUTHORIZED REPURCHASE OF UP TO $200 MILLION OF COMPANY'S COMMON STOCK.REVISING FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 28% TO 30%.FY2020 REVENUE VIEW $927.1 MILLION -- REFINITIV IBES DATA.

Abiomed Says CEO's FY 2019 Total Compensation Was $19.2 Mln Versus $10.3 Mln In FY 2018

June 25 (Reuters) - Abiomed Inc <ABMD.O>::ABIOMED INC SAYS CEO MICHAEL MINOGUE'S FY 2019 TOTAL COMPENSATION WAS $19.2 MILLION VERSUS $10.3 MILLION IN FY 2018 - SEC FILING.ABIOMED INC SAYS FOR FISCAL 2019, ESTIMATE RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN ANNUAL TOTAL COMPENSATION OF EMPLOYEES ABOUT 166 TO 1.

FDA Confirms Impella Rp Is Safe And Effective Only Right-Sided Device With FDA Approval

May 21 (Reuters) - Abiomed Inc <ABMD.O>::FDA CONFIRMS IMPELLA RP IS SAFE AND EFFECTIVE; ONLY RIGHT-SIDED DEVICE WITH FDA APPROVAL.ABIOMED INC - FDA CONFIRMS IMPELLA RP IS SAFE AND EFFECTIVE.ABIOMED INC - 18-MONTH PAS REPORT HAS BEEN ACCEPTED BY FDA AND IS SUCCESSFULLY CLOSED..ABIOMED INC - FDA HAS NO SAFETY CONCERNS ABOUT IMPELLA RP ITSELF.

FDA Approves Initiation Of STEMI DTU Pivotal Randomized Controlled Trial

May 2 (Reuters) - Abiomed Inc <ABMD.O>::FDA APPROVES INITIATION OF STEMI DTU PIVOTAL RANDOMIZED CONTROLLED TRIAL.ABIOMED - ON APRIL 26, FDA APPROVED INITIATION OF ST-ELEVATION MYOCARDIAL INFARCTION DOOR-TO-UNLOADING (STEMI DTU) PIVOTAL RANDOMIZED CONTROLLED TRIAL.

Abiomed Q4 GAAP Earnings Per Share $1.60

Abiomed Inc <ABMD.O>::ABIOMED ANNOUNCED Q4 FY 2019 REVENUE OF $207 MILLION AND 31.6% OPERATING MARGIN.Q4 GAAP EARNINGS PER SHARE $1.60.Q4 REVENUE $207.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $218.9 MILLION.SEES FY 2020 REVENUE UP 17 TO 23 PERCENT.SEES FY 2020 REVENUE $900 MILLION TO $945 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.08 -- REFINITIV IBES DATA.SAYS "Q4 DID NOT MEET OUR EXPECTATIONS".COMPANY IS GIVING ITS FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 29% TO 31%.FY2020 REVENUE VIEW $988.7 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up